Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1Отдел терапии психических заболеваний ФГБУ Московский научно-исследовательский институт психиатрии Минздрава России; 2Клиника первого психотического эпизода Психиатрического медицинского центра Минздрава Республики Армении
Список исп. литературыСкрыть список 1. Delay J, Deniker P, Harl JM. Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP). Ann Med Psychol (Paris) 1952; 110: 112–7. 2. Carlsson A, Lindqvist M, Magnusson T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957; 180: 1200. 3. Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on the formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh) 1963; 20: 140–4. 4. Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) 1987; 91: 415–33. 5. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261: 717–9. 6. Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975; 188: 1217–9. 7. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192: 481–3. 8. Snyder SH. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am J Psychiatry 1976; 133: 197–202. 9. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991; 148: 1474–86. 10. Pycock CJ, Kerwin RW, Carter CJ. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature 1980; 286: 74–6. 11. Scatton B, Worms P, Lloyd KG, Bartholini G. Cortical modulation of striatal function. Brain Res 1982; 232: 331–43. 12. Davidson LL, Heinrichs RW. Quantification of frontal and temporal lobe brain-imaging findings in schizophrenia: a meta-analysis. Psychiatry Res 2003; 122: 69–87. 13. Stahl SM. Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge University Press, 2008. 14. Howes OD, Kapur S. The Dopamine Hypothesis of Schizophrenia: Version III – The Final Common Pathway. Schizophr Bull 2009; 35 (9): 549–62. 15. van Os J. A salience dysregulation syndrome. Br J Psychiatry 2009; 2 (194): 101–3. 16. Мосолов С.Н. Некоторые актуальные теоретические проблемы диагностики, классификации, нейробиологии и терапии шизофрении: сравнение зарубежного и отечественного подходов. Журн. неврологии и психиатрии им. С.С.Корсакова. 2010; 6: 4–11. 17. Collier DA, Arranz MJ, Osborne S et al. Clozapine response and genetic variation in neurotransmitter receptor targets. In: Pharmacogenetics of Psychotropic Drugs. Ed. by B.Lerer. Cambridge University Press, 2004. 18. Weinberger DR. Schizophrenia drug says goodbye to dopamine. Nat Med 2007; 13 (9): 1018–9. 19. Berk M, Copolov D, Dean O et al. N-acetyl cysteine as a glutathione precursor for schizophrenia – a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008; 64 (5): 361–8. 20. Hyman SE. Revolution stalled. Sci Transl Med 2012; 4 (155). 21. Matthysse S. Antipsychotic drug actions: a clue to the neuropathology of schizophrenia? Fed Proc 1973; 32: 200–5.